Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160268 | 0.79 | — | — | |
| SCHEMBL11932071 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL25474447 | 0.78 | — | — | |
| SCHEMBL18760516 | 0.78 | — | — | |
| SCHEMBL23765298 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL23765253 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL24334879 | 0.77 | — | — | |
| SCHEMBL24920334 | 0.77 | — | — | |
| SCHEMBL19318434 | 0.75 | APLNR (0.33) | APLNR | |
| SCHEMBL25520267 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| US-8153626-B2 | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| WO-2007093515-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN LA-ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | APLNR 320/4885 |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | APLNR 1157/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | APLNR 1122/4885 |
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | APLNR 350/4885 |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | APLNR 1852/4885 |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | APLNR 4587/4885 |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | BRS3, BRSK1, BRSK2 | APLNR 173/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | APLNR 3366/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | APLNR 4246/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | APLNR 4524/4885 |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | APLNR 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.